Scientific publications for LFB

« Pharmacology, Efficacy and Safety of a Triple-Secured Fibrinogen Concentrate in Children Less than or Equal to 12 Years with Afibrinogenaemia”


A new scientific paper was published in the journal “Thrombosis and Haemostasis” in May 2020. This paper reports the pharmacokinetic parameters and safety and efficacy data, for LFB fibrinogen, from a prospective, multicenter, international Phase II-III clinical study. This study was conducted by LFB in children under 12 years of age with afibrinogenemia.

To find out more:





“Management of von Willebrand disease with a factor VIII-poor von Willebrand factor concentrate: results from a prospective observational post-marketing study”



Another study was also published in May 2020, in the “Journal of Thrombosis and Haemostasis”. This scientific publication concerns a prospective, observational, national post-marketing study of safety and efficacy of LFB’s Factor VIII-poor von Willebrand Factor in patients all ages, with a Willebrand disease, who were treated on a long-term basis.

To find out more: